Paper Details

  1. Home
  2. Paper Details

Calcium acetate versus calcium carbonate in the control of hyperphosphatemia in hemodialysis patients.

Author: HoetteM, KeenL N, LugonJ R, RuzanyF, d'Almeida FilhoE J, da CruzE A

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Calcium acetate was found to be a good alternative to calcium carbonate in controlling hyperphosphatemia in hemodialysis patients. A crossover, randomized, double-blind study involving 23 patients showed that calcium acetate was more effective at lowering phosphorus levels while causing less hypercalcemia.
Paper Details　
Original Abstract of the Article :
CONTEXT: Hyperphosphatemia has an important role in the development of bone and mineral abnormalities in end-stage renal disease (ESRD). OBJECTIVE: To compare the phosphorus binding power and the hypercalcemic effect of calcium acetate and calcium carbonate in hemodialysis patients. TYPE OF STUDY:...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1590/s1516-31802000000600006

データ提供：米国国立医学図書館（NLM）

Calcium Acetate: A Potential Game-Changer for Hyperphosphatemia in Hemodialysis Patients

In the vast desert of kidney disease, hyperphosphatemia is a persistent storm, brewing complications like bone and mineral abnormalities in end-stage renal disease (ESRD). This research, like a camel navigating a treacherous sand dune, delves into the intricate world of phosphorus binding agents. The authors conducted a crossover, randomized, double-blind study to compare the phosphorus binding power and hypercalcemic effect of calcium acetate and calcium carbonate in hemodialysis patients. The study, like a well-placed oasis, provided valuable insights into the therapeutic landscape of hyperphosphatemia.

Calcium Acetate: A New Oasis in the Desert of Hyperphosphatemia

This study discovered a significant increase in calcium plasma levels only after treatment with calcium carbonate. Meanwhile, both calcium acetate and calcium carbonate demonstrated a significant reduction in phosphorus levels. The authors suggest that calcium acetate might be a viable alternative to calcium carbonate in managing hyperphosphatemia in ESRD patients, potentially offering a lower risk of hypercalcemia.

Calcium Acetate: A New Path in the Desert of Hyperphosphatemia

The authors note that calcium acetate can potentially control hyperphosphatemia with a lower administration of calcium. This finding holds immense promise for ESRD patients, offering a path towards a healthier and more comfortable journey.

Dr.Camel's Conclusion

This study is a beacon of hope for those navigating the challenging terrain of ESRD. It provides a potential alternative to calcium carbonate, a treatment that is often associated with hypercalcemia. Further research is needed to confirm these findings and to explore the long-term effects of calcium acetate in ESRD patients. But one thing is for sure, we are one step closer to a brighter future for those who are facing hyperphosphatemia.

Date :
  1. Date Completed 2001-04-19
  2. Date Revised 2019-09-21
Further Info :

Pubmed ID

11120549

DOI: Digital Object Identifier

10.1590/s1516-31802000000600006

Related Literature

Article Analysis
・Side Effects of calcium acetate
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.